The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-06-30

Study Completion Date

2030-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study seeks to determine the biologic causes of inflammation in patients with Transverse Myelitis (TM) Neuromyelitis Optica Spectrum Disorder (NMOSD) and related conditions. While patients will be treated according to decisions with their treating physician, this study will collect data and samples from patients prospectively to gain a better understanding of the disease. We are seeking to understand why some patients respond to medications, while others do not. We also seek to understand what happens biologically, preceding relapses. Gathering these data and samples will allow researchers to identify new ways of diagnosing and treating these diseases. Data and samples will be shared with researchers around the world to support collaborative efforts to treat these conditions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarkers in Autoimmune Disease of Nervous System

NCT06502015

Autoimmune Diseases of the Nervous System Neuromyelitis Optica Spectrum Disorder Multiple Sclerosis +8 more

RECRUITING

Tongji NADs Cohort

NCT07333196

Multiple Sclerosis NMO Spectrum Disorder Autoimmune Encephalitis +6 more

NOT_YET_RECRUITING

Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT02629796

CIDP

COMPLETED

Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity

NCT06169150

Nervous System Disease Immune System Disease

RECRUITING

Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy

NCT04480450

Chronic Inflammatory Demyelinating Polyneuropathy

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study seeks to determine the biologic causes of inflammation in patients with Neuromyelitis Optica (NMO), Transverse Myelitis (TM), optic neuritis (ON), related conditions and healthy controls. While patients will be treated according to decisions with their treating physician, this study will collect data and samples from patients prospectively to gain a better understanding of the disease. We are seeking to understand why some patients respond to medications, while others do not. We also seek to understand what happens biologically, preceding relapses. Gathering these data and samples will allow researchers to identify new ways of diagnosing and treating these diseases. Data and samples will be shared with researchers around the world to support collaborative efforts to treat these conditions.

Patients will agree to share medical records, complete questionnaires and donate samples on a timed basis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuromyelitis Optica Neuromyelitis Optica Spectrum Disorder Transverse Myelitis Optic Neuritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neuromyelitis Optica Spectrum Disorder

Patients diagnosed with NMOSD based on revised diagnostic criteria. Seronegative, anti-AQP4 seropositive and ant-MOG seropositive patients will be included

No interventions assigned to this group

Transverse Myelitis and Optic Neuritis

Patients who have had one demyelinating event, not diagnosed with multiple sclerosis and whom are considered at risk for NMO or NMOSD.

No interventions assigned to this group

Healthy Controls

patients without a history of CNS inflammation

No interventions assigned to this group

Neuromyelitis Optica

patients diagnosed with NMO

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 6 years or greater
* Male or Female
* Patient or Parent (in the case of a minor) able to give informed consent
* For patients 10 to 17, patient able to assent
* Patient diagnosed with NMO, NMOSD, TM or ON